Form 4: Supernus Pharmaceuticals SVP & CFO Timothy Dec Reports Stock Option and Restricted Stock Unit Grant

Timothy C. Dec, Senior Vice President & CFO of Supernus Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Summary

• On February 19, 2025, Timothy C. Dec, the Senior Vice President & CFO of Supernus Pharmaceuticals, was granted stock options to purchase 40,000 shares of common stock at an exercise price of $33.52.
• These options vest in four equal annual installments starting on February 19, 2026, and expire on February 19, 2035.
• Dec also acquired 4,500 restricted stock units (RSUs), each representing the right to receive one share of Supernus common stock upon vesting.
• These RSUs vest in four equal annual installments beginning on February 19, 2026.
• Following these transactions, Dec beneficially owns 8,091 shares of Supernus common stock, which includes 901 shares acquired through the company's Employee Stock Purchase Plan.
• Dec also holds 40,000 stock options and 4,500 restricted stock units.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices. The grants incentivize the executive, which is generally viewed favorably.

Positives

• The grant of stock options and RSUs aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The vesting of the stock options and RSUs is contingent upon continued employment and achievement of any other performance conditions that may be in place but are not disclosed in this document.

Industry Context

Stock option and RSU grants are common forms of executive compensation in the pharmaceutical industry, used to incentivize performance and retain key personnel.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are typically benchmarked against peer companies in the pharmaceutical industry.
• Companies like Teva Pharmaceuticals, Mylan (now Viatris), and Amgen also utilize similar equity-based compensation strategies to align executive incentives with shareholder value.
• The specific terms of the grants, such as vesting schedules and exercise prices, are often tailored to the individual executive's role and responsibilities, as well as the company's overall performance goals.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates